Feedback

Advances in the study of death receptor 5

Affiliation
Graduate Collaborative Training Base of Academy of Military Medical Sciences ,Hengyang Medical School, University of South China ,Hengyang ,China
Qiao, Xuan;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Guo, Shuang;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Meng, Zhiyun;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Gan, Hui;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Wu, Zhuona;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Sun, Yunbo;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Liu, Shuchen;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Dou, Guifang;
Affiliation
Beijing Institute of Radiation Medicine ,Beijing ,China
Gu, Ruolan

DR5, a receptor with the highest affinity for TRAIL under physiological conditions, selectively induces apoptosis in specific target cells such as tumor and aberrant immune cells, while minimally affecting normal cells. The TRAIL-DR5 signaling pathway is a crucial regulatory mechanism when the body responds to various exogenous interference factors, including viruses, chemicals, and radiation. This pathway plays a vital role in maintaining physiological homeostasis and in the pathological development of various diseases. Different modulations of DR5, such as upregulation, activation, and antagonism, hold significant potential for therapeutic applications in tumors, cardiovascular diseases, autoimmune diseases, viral infections, and radiation injuries. This article provides an overview of the current research progress on DR5, including the status and prospects of its clinical applications.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Qiao, Guo, Meng, Gan, Wu, Sun, Liu, Dou and Gu.

Use and reproduction: